STOK

SEC source: 0001415889-24-028929 · form4-12112024_091251.xml · nonDerivative · entry 2

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,476

F3 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.24 per share, inclusive.

SEC source: 0001415889-24-028929 · form4-12112024_091251.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,028

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $14.22 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote (4).

SEC source: 0001415889-24-028928 · form4-12112024_091247.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,885

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.13 per share, inclusive.

SEC source: 0001415889-24-028892 · form4-12112024_121235.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,332

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.93 to $13.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-028891 · form4-12112024_121243.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,142

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.93 to $13.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-028890 · form4-12112024_121241.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,671

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.93 to $13.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-028396 · form4-12052024_091200.xml · derivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2025-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-24-028396 · form4-12052024_091200.xml · derivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2025-12-03

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-24-028396 · form4-12052024_091200.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-028398 · form4-12052024_091203.xml · derivative · entry 3

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2025-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-24-028398 · form4-12052024_091203.xml · derivative · entry 2

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2025-12-03

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-24-028398 · form4-12052024_091203.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-028397 · form4-12052024_091208.xml · derivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,500

Underlying: Common Stock · 26,500 shares

Expires 2025-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-24-028397 · form4-12052024_091208.xml · derivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,000

Underlying: Common Stock · 53,000 shares

Expires 2025-12-03

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-24-028397 · form4-12052024_091208.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,091

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-028889 · form4a-12102024_111228.xml · derivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,250

Underlying: Common Stock · 26,250 shares

Expires 2025-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-24-028889 · form4a-12102024_111228.xml · derivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 52,500 shares

Expires 2025-12-03

F1 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F2 · kind: This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

F3 · derivative.exercise_date: Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001415889-24-028889 · form4a-12102024_111228.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-028069 · form4-12032024_091239.xml · derivative · entry 5

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001415889-24-028069 · form4-12032024_091239.xml · nonDerivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,277

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.81 to $12.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-028069 · form4-12032024_091239.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-028069 · form4-12032024_091239.xml · derivative · entry 4

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,981

Underlying: Common Stock · 48,792 shares

Expires 2025-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: 48,792 restricted stock units vest on December 1, 2024 and 11,981 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

SEC source: 0001415889-24-028069 · form4-12032024_091239.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-028071 · form4-12032024_091216.xml · derivative · entry 2

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,357

Underlying: Common Stock · 33,927 shares

Expires 2025-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: 33,927 restricted stock units vest on December 1, 2024 and 12,357 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

SEC source: 0001415889-24-028071 · form4-12032024_091216.xml · nonDerivative · entry 1

Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,838

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported total includes an aggregate 2,313 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).

SEC source: 0001415889-24-028070 · form4-12032024_091257.xml · derivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,317

Underlying: Common Stock · 21,591 shares

Expires 2025-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: 21,591 restricted stock units will vest on December 1, 2024 and 4,317 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

SEC source: 0001415889-24-028070 · form4-12032024_091257.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,441

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-026135 · form4-11052024_091125.xml · derivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001415889-24-026135 · form4-11052024_091125.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,485

F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $12.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-026135 · form4-11052024_091125.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,485

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-024378 · form4-10022024_081008.xml · derivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 10,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001415889-24-024378 · form4-10022024_081008.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,485

F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.63 to $12.42 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-024378 · form4-10022024_081008.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,485

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001062993-24-016894 · form4.xml · nonDerivative · entry 1

Skorpios Trust · CIK 0001869333 · 10% owner

Blue Horizon Enterprise Ltd · CIK 0001869057 · 10% owner

Ezbon International Ltd · CIK 0001869027 · 10% owner

Montrago Trustees Ltd · CIK 0001869331 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 8,906,181

F1 · ownership.nature: Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 4,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 3,938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.

SEC source: 0001415889-24-022900 · form4-09052024_080953.xml · derivative · entry 4

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 10,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001415889-24-022900 · form4-09052024_080953.xml · nonDerivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,485

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.35 to $15.47 per share, inclusive.

SEC source: 0001415889-24-022900 · form4-09052024_080953.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,085

F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.35 to $15.34 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3, below.

SEC source: 0001415889-24-022900 · form4-09052024_080953.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,485

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-020734 · form4-08052024_080835.xml · derivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 10,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001415889-24-020734 · form4-08052024_080835.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,485

F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.18 to $14.94 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-020734 · form4-08052024_080835.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,485

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-019169 · form4-07032024_080758.xml · nonDerivative · entry 2

Nash Huw M. · CIK 0001780085 · Chief Business Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023.

SEC source: 0001415889-24-019169 · form4-07032024_080758.xml · nonDerivative · entry 1

Nash Huw M. · CIK 0001780085 · Chief Business Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33

F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).

SEC source: 0001415889-24-019168 · form4-07032024_080719.xml · derivative · entry 3

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 10,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This fully-vested option vested as to 1/4th of the total award on October 2, 2018, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001415889-24-019168 · form4-07032024_080719.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,485

F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2023.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.47 to $14.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-24-019168 · form4-07032024_080719.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,485

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-015962 · form4-06072024_080601.xml · derivative · entry 1

Krainer Adrian R. · CIK 0001780081 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,639

Underlying: Common Stock · 7,639 shares

Expires 2034-06-04

F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

SEC source: 0001415889-24-015964 · form4-06072024_080608.xml · derivative · entry 1

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,639

Underlying: Common Stock · 7,639 shares

Expires 2034-06-04

F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

SEC source: 0001415889-24-015991 · form4-06072024_080638.xml · derivative · entry 1

Harrison Seth Loring · CIK 0001404955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,639

Underlying: Common Stock · 7,639 shares

Expires 2034-06-04

F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.